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Introduction: We assessed rates and predictive factors of non-invasive ventilation (NIV) failure in patients admitted
to the intensive care unit (ICU) for non-hypercapnic acute hypoxemic respiratory failure (AHRF).
Methods: This is an observational cohort study using data prospectively collected over a three-year period in a
medical ICU of a university hospital.
Results: Among 113 patients receiving NIV for AHRF, 82 had acute respiratory distress syndrome (ARDS) and 31
had non-ARDS. Intubation rates significantly differed between ARDS and non-ARDS patients (61% versus 35%,
P = 0.015) and according to clinical severity of ARDS: 31% in mild, 62% in moderate, and 84% in severe ARDS
(P = 0.0016). In-ICU mortality rates were 13% in non-ARDS, and, respectively, 19%, 32% and 32% in mild, moderate
and severe ARDS (P = 0.22). Among patients with moderate ARDS, NIV failure was lower among those having a
PaO2/FiO2 >150 mmHg (45% vs. 74%, p = 0.04). NIV failure was associated with active cancer, shock, moderate/
severe ARDS, lower Glasgow coma score and lower positive end-expiratory pressure level at NIV initiation. Among
intubated patients, ICU mortality rate was 46% overall and did not differ according to the time to intubation.
Conclusions: With intubation rates below 35% in non-ARDS and mild ARDS, NIV stands as the first-line approach;
NIV may be attempted in ARDS patients with a PaO2/FiO2 > 150. By contrast, 84% of severe ARDS required
intubation and NIV did not appear beneficial in this subset of patients. However, the time to intubation had no
influence on mortality.Introduction
It is now well-demonstrated that non-invasive ventilation
(NIV) can reduce intubation and mortality rates in patients
with severe acute exacerbation of chronic obstructive pul-
monary disease [1-3] or cardiogenic pulmonary edema [4].
By contrast, the beneficial effects of NIV remain unclear in
patients with de novo acute hypoxemic respiratory failure
(AHRF), that is, non-hypercapnic patients having acute
respiratory failure in the absence of a cardiac origin or
underlying chronic pulmonary disease. NIV is more likely
to fail in hypoxemic patients [5], and NIV failure could be
associated with increased mortality [6]. In unselected pa-
tients admitted to ICUs for AHRF, the rate of intubation is* Correspondence: aw.thille@gmail.com
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reproduction in any medium, provided the orparticularly high, reaching 60% [6,7], and their in-ICU
mortality after intubation may exceed 60% [6-8]. Thus,
NIV may improve outcome of patients who succeed in
NIV by avoiding intubation, but may worsen outcome by
delaying intubation in those having failed NIV.
Despite these concerns, surveys show that NIV is in-
creasingly used in patients having AHRF and is initiated
as first-line ventilatory support in 20% to 30% of such
patients [5,7]. NIV has even been used as the first-line
ventilatory support in patients having clinical criteria
for acute respiratory syndrome (ARDS) [9,10] with a
success rate of more than 50%, especially in patients
with prompt improvement of oxygenation [9]. The in-
creasing popularity of NIV in AHRF patients is sup-
ported by some studies showing that NIV markedly
reduced intubation and mortality rates in immunosup-
pressed patients [11,12] or in selected surgical patients
with AHRF [13,14].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conducted in non-immunosuppressed patients with
AHRF [15-18], and some of these included hypercapnic
patients [15,16]. To date, only two randomized con-
trolled studies have evaluated NIV in non-hypercapnic
patients with AHRF [17,18], with one suggesting that
NIV may reduce intubation rate and even mortality [18]
and the other reporting no beneficial effects of continu-
ous positive-end expiratory pressure without ventilatory
assistance [17].
The aims of our study were to assess the rate of NIV
failure in patients admitted for AHRF according to the
presence and clinical severity of ARDS as recently de-
fined [19], and to identify early predictors of NIV failure.
Material and methods
This observational cohort study was conducted in our 24-
bed medical ICU at Henri Mondor University Hospital in
Créteil, France. The Institutional Review Board of the
French Society for Respiratory Medicine approved this
non-interventional study and waived the need for in-
formed consent.
Patients
All consecutive patients admitted during a three-year
period (June 2008 to June 2011) and who received NIV as
initial ventilatory support for AHRF were included. AHRF
was defined as recent dyspnea with a respiratory rate >25
breaths/minute and/or sternocleidomastoid muscle activa-
tion with pulmonary infiltrates on chest X-ray, and a
PaCO2 below or equal to 45 mmHg. We excluded patients
who were intubated before ICU admission or intubated
upon ICU admission without prior NIV, and patients for
whom NIV was used with a “do not intubate” order. How-
ever, the outcome for those who were directly intubated
for acute respiratory failure without prior NIV, and who
met clinical criteria for moderate or severe ARDS was also
collected. The study was conducted after the implementa-
tion of a nurse-driven NIV protocol which included pro-
spective daily collection of clinical data and ventilatory
parameters on a specific NIV monitoring form. When the
NIV form was unavailable or incomplete, data were re-
trieved from the patient’s records.
Non-invasive ventilation protocol and definitions
All stages of the protocol had been developed within a
multidisciplinary working group including ICU physi-
cians, nurses and respiratory therapists. The protocol
aimed at empowering nurses to adjust the ventilatory
settings and to improve the patient's tolerance to NIV
following a simple decision algorithm. A daily NIV pre-
scription by the physician indicated the duration of NIV
sessions and targeted expiratory tidal volume (around 6
to 8 ml/kg) and oxygen saturation (SpO2) (≥94%).Pressure-support (PS) ventilation was started using a
pressure-support level of 8 cmH2O, a positive end-
expiratory pressure (PEEP) level of 5 cmH2O, an inspira-
tory trigger of 3 L/minute, and a maximal inspiratory
time of one second. The nurses then adjusted the venti-
latory parameters, including pressure-support level and
FiO2 (fraction of inspired oxygen), according to the
protocol. Pressure-support level was gradually increased
by 2 cmH2O steps to reach the target expiratory tidal
volume and PEEP level was then adjusted as prescribed.
FiO2 was gradually adjusted by 5% steps to reach the tar-
geted SpO2. Non-invasive ventilation was applied inter-
mittently for periods of at least two hours, with a
minimal duration of six hours per day and was main-
tained until signs of respiratory distress improved. An al-
gorithm was used by nurses in case of leaks, which
involved first repositioning of the mask; second, redu-
cing the PEEP level at 2 cmH2O; third, reducing the
pressure-support level by steps of 2 cmH2O until the
minimal expiratory volume was reached; and fourth,
changing the mask interface.
A mobile cart containing all types and sizes of inter-
faces was available at the bedside during initiation of
NIV. NIV was performed via a non-vented full-face
mask (FreeMotion™ RT041, Fisher & Paykel, Auckland,
New Zealand or Ultra Mirage™, Resmed, CA, USA), with
an ICU ventilator using a dedicated NIV mode (Evita
XL, Dräger, Lübeck, Germany, or Engström Carestation,
GE Healthcare, Fairfield, CT, USA), equipped with a
heated humidifier (MR850, Fisher & Paykel).
The following criteria were used for endotracheal in-
tubation: loss of consciousness or psychomotor agitation
hindering nursing care and requiring sedation; persistent
hypotension (defined by systolic arterial blood pressure
below 90 mmHg or mean arterial blood pressure below
65 mmHg) despite fluid resuscitation, or need for vaso-
pressors; or two of the following criteria: frank worsen-
ing of respiratory distress under NIV, respiratory rate
above 40 breaths per minute, SpO2 remaining below
90% despite FiO2 100%, dependence to NIV for more
than 12 hours, or pH <7.35. NIV failure was defined by
the need for endotracheal intubation.
Data collection
From the NIV monitoring forms, we analyzed the num-
ber and duration of NIV sessions, ventilator settings
(pressure support level, positive end-expiratory pressure,
FiO2), ventilatory parameters (SpO2, respiratory rate, ex-
piratory tidal volume), hemodynamic parameters (heart
rate, blood pressure and level of consciousness assessed
using the Richmond Agitation-Sedation Scale (RASS)
[20], with altered consciousness defined as a RASS <0.
NIV tolerance and number of leaks were recorded on a
4-point scale, then dichotomized into “acceptable”
Figure 1 Flow-chart of the study. Among the 1,163 patients
admitted for acute respiratory failure, 465 patients received NIV over
a three-year period. After excluding 35 patients who received NIV
with a “do not intubate” order, 430 received NIV of which 242 had
acute hypercapnic respiratory failure and 188 had acute hypoxemic
respiratory failure. After excluding 69 patients who received NIV for
cardiogenic pulmonary edema and 6 patients without pulmonary
infiltrates, 113 patients had non-hypercapnic acute hypoxemic
respiratory failure. (ARDS, acute respiratory distress syndrome;
NIV, Non-invasive ventilation).
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“minor” (scored 0 to 1) or “major” (scored 2 to 3) leaks,
respectively. Blood gases were routinely measured one
hour after initiation of NIV. Clinical data (respiratory
rate, SpO2, blood pressure, heart rate, Glasgow coma
score) and blood gases at admission before NIV initi-
ation were retrospectively collected from the medical
chart. We also recorded the occurrence of shock at ad-
mission or at initiation of NIV (defined by hypoperfu-
sion signs and administration of at least 30 ml/kg fluids,
dobutamine or vasopressors).
Patients were stratified according to the presence of
clinical criteria for ARDS. The severity of ARDS was
stratified using the recent Berlin definition [19], ac-
cording to the value of oxygenation recorded within
the first hour after NIV initiation, and classified as mild
(201 ≤ PaO2/FiO2 (partial pressure of oxygen/fraction of
inspired oxygen) ≤ 300 mmHg), moderate (101 ≤ PaO2/
FiO2 ≤ 200 mmHg) or severe (PaO2/FiO2 ≤ 100 mmHg).
Statistical analysis
Dichotomous variables are reported as number (percent-
age), and were compared using the chi-square or Fisher’s
exact tests. Continuous variables are expressed as mean
(± standard deviation) or as median and interquartile
range (IQR, (25th to 75th percentiles)) after testing their
normal distribution using the Shapiro-Wilk test. Groups
were compared using the unpaired Student’s t-test or
Wilcoxon rank-sum and Kruskall-Wallis tests, when ap-
propriate. Odds ratios (OR) with 95% confidence inter-
vals (CI) were used to describe differences between
subgroups for NIV failure or death.
Survival without intubation was tested using Kaplan-
Meier estimates and compared with the log-rank test.
To evaluate independent factors associated with NIV
failure, variables with a univariate P-value <0.10 were en-
tered in a Cox proportional hazards model with time to
intubation as the dependent variable, censoring data at
ICU discharge. Among related variables, the most sig-
nificant or clinically relevant was entered into the model
in order to minimize the effect of colinearity. Because it
was measured at 24 hours after admission, the general
severity score SAPS 2 was not included in this analysis.
Variables included in the model are reported with their
corresponding hazard ratio (HR) and 95% CI. We consid-
ered two-tailed P-values <0.05 as significant. Statistical
analyses were performed using the statistical software
package STATA version 10.1 (Stata Corp., TX, USA).
Results
Patients
Among 430 patients who received NIV during the study
period, 188 had non-hypercapnic acute respiratory failure.
After excluding patients with cardiogenic pulmonaryedema and those without pulmonary infiltrates, 113 had
de novo acute hypoxemic respiratory failure (Figure 1).
Eighty-two patients had clinical criteria for ARDS at the
time of NIV initiation, including 16 with mild (20%), 47
with moderate (57%) and 19 (23%) with severe ARDS.
ARDS was due to bacterial pneumonia (n = 21), viral
pneumonia (n = 7), pneumocystis jirovecii (n = 4), pneu-
monia without microbiological documentation (n = 24),
aspiration (n = 5), alveolar hemorrhage (n = 6), drug in-
duced pneumonia (n = 5), extra-pulmonary sepsis (n = 8),
transfusion acute lung injury (n = 1), and fat embolism
(n = 1). The 31 remaining patients without clinical cri-
teria for ARDS (non-ARDS) had pneumonia (n = 17), atel-
ectasis (n = 5), aspiration (n = 4), intra-alveolar hemorrhage
(n = 2), pleural effusion (n = 2) or extra-pulmonary sepsis
(n = 1). Overall, 50 patients (44%) were immunocom-
promised (Table 1), because of hematologic malignancy
(n = 22), organ transplant (n = 10), HIV infection (n = 6),
vasculitidis or steroid therapy (n = 4) or active/metastatic
solid cancer (n = 8).
Rates of NIV failure and in-ICU mortality
The rate of intubation was 61% (50/82) in ARDS and
35% (11/31) in non-ARDS patients (P = 0.015). This rate
did not differ between patients without ARDS or those
with mild ARDS (P = 0.71), but increased with increasing
clinical severity of ARDS from 31% (5/16) in mild, 62%
(29/47) in moderate, to 84% (16/19) in severe ARDS
(P = 0.0016) (Figure 2). Patients with moderate or severe
ARDS were twice as likely to fail NIV (45/66, 68%) than
Table 1 Characteristics and outcomes of the patients
receiving NIV for non-hypercapnic AHRF
No ARDS or mild
ARDS (n = 47)
Moderate or severe
ARDS (n = 66)
P
Age, mean, years 60 (± 15) 61 (± 17) 0.72
Male sex, n (%) 30 (64%) 45 (68%) 0.62
SAPS II, points* 33 (23 to 39) 41 (30 to 51) 0.0014
Immunosuppression
or cancer, n (%)




Sepsis, n (%) 27 (73%) 53 (70%) 0.72
Systolic arterial
pressure, mmHg
131 (± 25) 127 (± 27) 0.43
Heart rate, beats/
minute
114 (± 25) 110 (± 26) 0.43
Respiratory rate,
cycles/minute
33 (± 7) 33 (± 7) 0.78
Glasgow coma scale,
points*
15 (15 to 15) 15 (15 to 15) 0.75
pH, units* 7.4 (7.43 to 7.49) 7.45 (7.40 to 7.48) 0.24
PaCO2, mm Hg 34.6 (± 6.3) 35.4 (± 5.0) 0.43
PaO2, mm Hg 77 (± 41) 85 (± 54) 0.43
Bicarbonates, mmol/L 25.0 (± 4.8) 24.5 (± 5.0) 0.58
Lactates, mmol/L* 1.4 (1.0 to 2.0) 1.9 (1.1 to 2.6) 0.054
At 1 h of NIV
initiation
pH* 7.46 (7.39 to 7.49) 7.42 (7.38 to 7.46) 0.03
PCO2, mm Hg 36.1 (± 6.6) 37.8 (± 7.4) 0.21
PaO2/FiO2, mm Hg* 266 (219 to 330) 124 (94 to 164) <0.0001
PEEP level, cm H2O 4.7 (± 1.1) 4.5 (± 1.1) 0.46
PS level, cm H2O* 8.0 (6.5 to 10) 8.0 (6 to 8) 0.46
Tidal volume, ml 579 (± 174) 613 (± 173) 0.37
Respiratory rate,
breaths/minute*
34.5 (25 to 40) 32 (26 to 37.5) 0.45
Outcome
Duration of NIV Day 1,
hours*
6.8 [4.0 to 10.0] 5.2 [2.0 to 10.0] 0.19
Total duration of
NIV, days*
2.0 [1.0 to 3.0] 1.0 [1.0 to 2.5] 0.17
Rate of NIV Failure,
n (%)
16 (34%) 45 (68%) 0.0003
Length of stay in
ICU, days*
8.0 [5.0 to 15.0] 10.0 [6.0 to 14.0] 0.53
ICU mortality, n (%) 7 (15%) 21 (32%) 0.04
Values are given as mean (± standard deviation) or as median [IQR, 25th to 75th]
for non-normally distributed variables (*).
AHRF, Acute Hypoxemic Respiratory Failure; ARDS, Acute Respiratory Distress
Syndrome; ICU, Intensive Care Unit; NIV, Non-Invasive Ventilation; SAPS II,
Simplified Acute Physiology Score II.
Figure 2 Rates of NIV failure and in-ICU mortality (expressed
in %) according to clinical criteria for acute respiratory distress
syndrome (ARDS) and clinical severity of ARDS using the Berlin
definition. Intubation rate was significantly different between the four
groups (P = 0.001) but not the mortality rate (P = 0.22). Intubation and
mortality rates were higher in patients with moderate or severe ARDS
than in patients with mild or without clinical criteria for ARDS.
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(OR = 4.15, 95% CI: 1.78 to 9.70; P = 0.0004) Survival
analysis showed that intubation rates differed markedly
(P <0.00001, Log-rank test) between patients with no or
mild ARDS and those with moderate or severe ARDS
(Figure 3).
Overall in-ICU mortality rate was 25% (28/113), and
tended to be higher in patients with ARDS (24/82, 29%)
than others (4/31, 13%, P = 0.07) (Figure 2). The mortality
rate of patients with moderate or severe ARDS was also
twice as high (21/66; 32%) as those with no or mild ARDS
(7/47; 15%) (OR = 2.7; 95% CI: 1.003 to 7.09; P = 0.041).
Among intubated patients, the overall in-ICU mortal-
ity rate was 46% (28/61). Thirty-three patients (54%)Figure 3 Kaplan-Meier estimate of survival without intubation
according to presence of ARDS and its severity at presentation,
stratified as no ARDS or mild ARDS (solid line) or moderate or
severe ARDS (dashed line). The difference between the two
groups was highly significant (P <0.0001, log-rank test). (ARDS,
acute respiratory distress syndrome).
Figure 5 Rate of in-ICU mortality in patients with moderate or
severe ARDS. No difference was found in patients who were
intubated after NIV failure as compared to those who were directly
intubated for acute respiratory failure without prior NIV (at right).
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tients remaining (46%) were intubated beyond 24 hours.
The delay between NIV initiation and intubation had no
influence on outcome with a similar time to intubation
in survivors and non-survivors (Figure 4). Among pa-
tients with moderate or severe ARDS, in-ICU mortality
was similar in patients who were intubated after failure
of NIV as compared to patients who were directly intu-
bated without prior NIV (Figure 5).
Factors associated with NIV failure
Prospective data from NIV monitoring forms were avail-
able for 81% (91/113) of patients. Patients who were not
intubated received NIV during a longer duration than
those who were intubated (3.3 ± 2.8 days versus 2.0 ±
2.0 days, P = 0.006). Patients who failed NIV had lower
PEEP levels and poorer tolerance to NIV than patients
who succeeded NIV. Patients who failed NIV had more
often active cancer, shock on admission and moderate/
severe ARDS. They also had a higher SAPS II score, a
lower Glasgow coma score, and a lower PaO2/FiO2 ratio
(Table 2). Among patients with moderate ARDS, those
with a PaO2/FiO2 ratio <150 were at significantly higher
risk of intubation: 20/27 (74%) vs. 9/20 (45%); HR = 2.3
(95% CI, 1.04 to 5.06); P = 0.04. The rate of microbio-
logical documentation was similar in patients who suc-
ceeded NIV as compared to those who failed NIV: 44%
(23/52) in the success group versus 49% (30/61) in the
failure group (P = 0.70).
Cox regression analysis showed that the risk of intub-
ation was significantly associated with active cancer, a
lower Glasgow coma score, shock, moderate/severe ARDS
and a lower PEEP level (Table 2).Figure 4 Box-plots indicating the median delay (25th to 75th
percentiles) between NIV initiation and intubation in patients
intubated within the first 96 h. The time to intubation was similar in
survivors (at left) and non-survivors (at right). Only five patients (three
survivors and two non-survivors) were intubated beyond 96 hours.Discussion
In our study, the intubation rate was higher in ARDS pa-
tients (61%) than in non-ARDS patients (35%). However,
the 31% intubation rate in mild ARDS was close to that of
non-ARDS, whereas it significantly increased up to 62% in
moderate ARDS and to 84% in severe ARDS. After adjust-
ment, underlying active cancer, moderate or severe ARDS,
shock, lower Glasgow Coma Score (GCS) and lower PEEP
level at NIV initiation were predictors of intubation. After
NIV initiation, the time to intubation in patients who
failed NIV did not influence outcome.
NIV failure rate in patients with acute hypoxemic
respiratory failure
In patients receiving NIV for AHRF, we found an overall
rate of intubation of 54%, which is substantially higher
than the 25 to 35% rate reported in randomized con-
trolled trials evaluating NIV in AHRF [17,18]. However,
in these two studies nearly 20 to 30% of the patients re-
ceived NIV for cardiogenic pulmonary edema. Moreover,
patients enrolled in such randomized studies are selected
and, consistent with our results, intubation rates up to
60% have been reported in a series of unselected patients
with AHRF of non-cardiac origin [6-8].
In their analysis of 147 ARDS patients receiving NIV
as first-line therapy, Antonelli et al. [9] reported an in-
tubation rate of only 46%. In this study, a high SAPS 2
(> 34) and low PaO2/FiO2 ratio (≤ 175 mmHg) after NIV
initiation were the two risk factors of NIV failure, with an
intubation rate of 78% (25/32) when both risk factors were
present [9]. Although our overall intubation rate was
higher, the intubation rate of patients presenting with the
combination of these two criteria was strictly similar (79%,
27/34) and their mortality rate was likewise similar. How-
ever, using the SAPS 2 is clinically impractical since this
score is computed only after 24 hours of admission,
Table 2 Predictors of endotracheal intubation in patients receiving NIV for non-hypercapnic AHRF
NIV Success N = 52 NIV Failure N = 61 Univariate HR [95% CI];
P-value
Cox regression aHR [95% CI];
P-value
Age, years 58.0 (± 17.1) 62.6 (± 14.4) 1.47 [0.99 to 1.02]; P = 0.142 -
Male sex, n (%) 36 (69%) 39 (64%) 0.85 [0.51 to 1.44]; P = 0.551 -
SAPS II 31.4 (± 10.9) 46.3 (± 18.2) 1.05 [1.03 to 1.06]; P <0.001 Not included
Immunosuppression/cancer, n (%) 20 (38%) 30 (49%) 1.30 [0.79 to 2.16]; P = 0.169 -
Cancer, n (%) 0 (0%) 8 (13%) 4.36 [2.01 to 9.44]; P <0.001 2.74 [1.22 to 6.15]; P = 0.014
At Admission before VNI
Sepsis, n (%) 37 (71%) 43 (70%) 0.97 [0.56 to 1.68]; P = 0.913 -
Glasgow coma score 14.9 (± 0.5) 14.6 (± 1.2) 0.84 [0.69 to 1.03]; P = 0.098 0.77 [0.63 to 0.96]; P = 0.018
Respiratory Rate, breaths/minute 32.7 (± 7.0) 33.3 (± 6.6) 1.01 [0.97 to 1.05]; P = 0.517 -
pH 7.44 (± 0.06) 7.44 (± 0.08) 2.16 [0.05 to 89.3]; P = 0.685 -
PaO2, mm Hg 78.7 (± 43.0) 84.1 (± 53.2) 1.00 [0.99 to 1.01]; P = 0.442 -
PaCO2, mm Hg 34.8 (± 5.6) 35.3 (± 6.0) 1.01 [0.97 to 1.06]; P = 0.669 -
Bicarbonates, mmol/L 24.4 (± 4.8) 25.5 (± 5.0) 1.01 [0.96 to 1.06]; P = 0.547 -
Lactates, mmol/L 2.0 (± 1.8) 1.9 (± 1.2) 1.00 [0.85 to 1.18]; P = 0.940 -
Heart rate, beats/minute 114 (± 27) 110 (± 25) 0.99 [0.98 to 1.01]; P = 0.467 -
Shock, n (%) 4 (8%) 14 (23%) 2.08 [1.14 to 3.79]; P = 0.017 1.89 [1.01 to 3.53]; P = 0.047
Systolic arterial pressure, mmHg 134 (± 27) 124 (± 24) 0.99 [0.98 to 1.00]; P = 0.055 Not included
At NIV initiation
Altered consciousness, n (%) 3 (6%) 8 (13%) 1.71 [0.81 to 3.59]; P = 0.158 -
pH 7.43 (± 0.06) 7.41 (± 0.10) 0.12 [0.00 to 4.31]; P = 0.244 -
PCO2, mm Hg 36.6 (± 6.7) 37.5 (± 7.5) 1.02 [0.98 to 1.05]; P = 0.327 -
PaO2/FiO2, mm Hg 211 (± 86) 163 (± 92) 0.99 [0.99 to 0.99]; P = 0.003 Not included
Moderate or severe ARDS, n (%) 21 (40%) 45 (74%) 2.79 [1.57 to 4.95]; P < 0.001 2.57 [1.33 to 4.75]; P = 0.003
PaO2/FiO2 <150 mm Hg, n (%) 12 (23%) 37 (61%) 2.97 [1.77 to 4.99]; P < 0.001 Not included
PEEP level, cm H2O 4.8 (± 1.0) 4.4 (± 1.3) 0.77 [0.62 to 0.94]; P = 0.011 0.71 [0.57 to 0.88]; 0.002
PS level, cm H2O 8.1 (± 2.2) 8.0 (± 1.9) 0.98 [0.86 to 1.13]; P = 0.915 -
Tidal volume, ml 576 (± 144) 619 (± 196) 1.00 [0.99 to 1.00]; P = 0.157 -
Respiratory rate, breaths/minute 32.7 (± 12.9) 33.9 (± 9.0) 1.01 [0.98 to 1.03]; P = 0.601 -
Important leaks, n (%) 2/43 (5%) 3/48 (6%) 1.39 [0.43 to 4.48]; P = 0.720 -
Poor tolerance, n (%) 3/43 (7%) 9/48 (19%) 2.08 [1.00 to 4.30]; P = 0.049 1.97 [0.89 to 4.30]; P = 0.09
Values are given as mean (± standard deviation) or proportion (%).
AHRF, Acute Hypoxemic Respiratory Failure; ARDS, Acute Respiratory Distress Syndrome; CI, 95% Confidence Interval HR; Hazard Ratio (aHR, adjusted HR);
NIV, Non-Invasive Ventilation; PEEP, Positive End-Expiratory Pressure; PS, Pressure Support; SAPS II, Simplified Acute Physiology Score; VT, Tidal Volume.
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of intubation in patients who failed NIV within the first
24 hours.
Time to intubation and impact on outcome
It has been suggested that NIV failure in patients with
AHRF is independently associated with poor outcome as
compared to patients intubated without prior NIV [6].
Therefore, it is essential to assess intubation rates and
the impact of NIV failure on outcome in different sub-
sets of the population with AHRF. It was recently sug-
gested at an international conference that NIV may be a
first line treatment in mild ARDS [21]. Our studysupports this contention, as the intubation rate in pa-
tients with mild ARDS did not differ from that recorded
in non-ARDS patients. In our patients with moderate or
severe ARDS, however, the intubation rate was much
higher (68%). Nevertheless, the mortality rate of patients
failing NIV did not differ according to the time to intub-
ation, in contrast with previous studies of patients with
community acquired pneumonia [22] or receiving NIV
during the post-extubation period [23]. We were unable
to identify a time beyond which maintaining NIV may
worsen outcome, and we believe that intubation should
be decided according to standard criteria regardless of
NIV duration.
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in moderately ill patients, while more severe patients
would have been intubated without prior NIV. However,
the rate of severe ARDS (19/82, 23%) in our population
is close to that reported in the recent Berlin definition
[19]. Mortality rates observed in intubated patients with
ARDS are usually higher in observational studies than in
randomized controlled studies and can reach 45% in un-
selected cohorts of patients [24,25]. Thus, our mortality
rate of 48% in ARDS patients who failed NIV and re-
quired intubation is in line with these cohort studies of
intubated patients.
Predictive factors for NIV failure
As previously reported [6], immunosuppression had no
influence on the success or failure of NIV; however, all
eight patients in the subgroup having active or meta-
static cancer failed NIV, and this factor remained signifi-
cantly associated with NIV failure after adjustment
(Table 2); thus, using NIV in this subgroup should be
carefully considered. Not surprisingly, a low GCS and, to
a lesser extent, shock were associated with NIV failure.
Although neither controlled studies [17,18] nor surveys
[5,7] found that the occurrence of shock was a risk fac-
tor of intubation, two others studies found that shock
was associated with NIV failure [8,22].
Several studies found that hypoxemia was independently
associated with NIV failure [7-9,22]. Our results confirm
that stratification of patients according to the clinical se-
verity of ARDS using the recent Berlin definition was
clearly associated with the risk of NIV failure, with a low
risk in patients with mild ARDS, increasing to 84% in
those who had a PaO2/FiO2 ≤100 mmHg at initiation of
NIV. However, a cut-off of 150 mmHg (a value close to
that reported by Antonelli et al. [9]) appeared to more ac-
curately segregate patients who failed from those who suc-
ceeded NIV. Therefore, whereas almost all patients with
severe ARDS are likely to fail NIV, some patients with
“moderate” ARDS might still benefit from a NIV trial.
Limitations
Our study was conducted in a single unit with a long-
standing experience in the practice of NIV and, there-
fore, our results may not be applicable to other centers
with less extensive experience. Experience and nurse-
driven protocols may improve NIV tolerance, and we re-
port a poor tolerance rate of only 13% after one hour of
NIV. In line with previous studies [5], poor tolerance
was associated with NIV failure in univariate analysis
but not after adjustment for other variables associated
with NIV failure. However, whereas rate of NIV failure
could be significantly reduced for hypercapnic patients
in experienced centers [26], our rate of intubation was
not lower in this series than in surveys including lessexperienced centers [5,7]. Another limitation is the
retrospective nature of the study. However, prospective
data collection of ventilatory parameters under NIV was
available for a vast majority of our patients and, because
of the availability of computerized medical charts for all
patients, all those receiving NIV for AHRF could be
analyzed.
Conclusion
The major implications of our results are to easily iden-
tify hypoxemic patients who may benefit from NIV. In-
tubation rates did not exceed 35% in non-ARDS and
mild ARDS and NIV may thus be used as the first-line
ventilatory support, as recently suggested [21]. By con-
trast, 84% of severe ARDS required intubation and NIV
does not appear beneficial in this subset of patients;
however, the time to intubation after NIV failure did
not seem to influence outcome of patients. In patients
with moderate ARDS, NIV may be worth attempting in
those having a PaO2/FiO2 ratio >150 in the absence of
hemodynamic instability or altered consciousness; fur-
ther studies are needed to define the most appropriate
use of NIV in these patients.
Key messages
 Intubation rates significantly differed between ARDS
and non-ARDS patients and according to clinical
severity of ARDS: 31% in mild, 62% in moderate and
84% in severe ARDS.
 NIV may be used as the first-line ventilatory support
in mild ARDS whereas it does not appear beneficial
in severe ARDS.
 In patients with moderate ARDS, NIV may be worth
attempting in those having a PaO2/FiO2 ratio >150.
 The time to intubation after NIV failure did not
seem to influence outcome of patients.
 Active cancer, shock, moderate/severe ARDS, lower
Glasgow coma score and lower positive end-
expiratory pressure level at NIV initiation were
predictors of NIV failure.
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